Low-dose, subcutaneous anti-CD20 therapy effectively depletes B-cells and ameliorates CNS autoimmunity

被引：0
|
作者：
Huck, C. [1 ]
Wegert, V. [1 ]
Schmid, C. [1 ]
Dunn, B. [2 ]
Smith, P. [1 ]
机构：
[1] Novartis Inst BioMed Res, Basel, Switzerland
[2] Novartis Inst Funct Genom Inc, San Diego, CA USA
来源：
MULTIPLE SCLEROSIS JOURNAL | 2016年 / 22卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P401
引用
收藏
页码：164 / 164
页数：1
相关论文
共 50 条
  • [21] Autoreactive B-cells phenotype analysis in pemphigus patients before and after anti-CD20 treatment
    Vaillant, M. Maho
    Golinsky, M.
    Caillot, F.
    Hebert, V.
    Petit, M.
    Riou, G.
    Boyer, O.
    Joly, P.
    Calbo, S.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2017, 137 (10) : S199 - S199
  • [22] Functional characterization of reappearing B cells after anti-CD20 treatment of CNS autoimmune disease
    Haeusler, Darius
    Haeusser-Kinzel, Silke
    Feldmann, Linda
    Torke, Sebastian
    Lepennetier, Gildas
    Bernard, Claude C. A.
    Zamvil, Scott S.
    Brueck, Wolfgang
    Lehmann-Horn, Klaus
    Weber, Martin S.
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2018, 115 (39) : 9773 - 9778
  • [23] MODULATION OF CD20 EXPRESSION ON B CELLS BY ANTI-CD20 ANTIBODIES
    Bellintani, Elaine C.
    de Marco, Renato
    Fantini, Renata
    Valim, Tiago
    Macedo, Denise
    Miyamoto, Yuriko
    Temin, Julia
    Gerbase-DeLima, Maria
    HUMAN IMMUNOLOGY, 2016, 77 : 138 - 138
  • [24] Subcutaneous injections of low-dose veltuzumab (humanized anti-CD20 antibody) are safe and active in patients with indolent non-Hodgkin's lymphoma
    Negrea, George O.
    Elstrom, Rebecca
    Allen, Steven L.
    Rai, Kanti R.
    Abbasi, Rashid M.
    Farber, Charles M.
    Teoh, Nick
    Horne, Heather
    Wegener, William A.
    Goldenberg, David M.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2011, 96 (04): : 567 - 573
  • [25] Targeting CD20+ Rituxan resistant B-cells with anti-CD3 activated T cells (ATC) armed with anti-CD3 x anti-CD20 (CD20Bi)
    Gall, JM
    Grabert, RC
    Deavers, M
    Davoll, PA
    Lum, LG
    EXPERIMENTAL HEMATOLOGY, 2004, 32 (07) : 35 - 35
  • [26] Anti-CD20 Antibody Therapy for B-Cell Lymphomas
    Maloney, David G.
    NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (21) : 2008 - 2016
  • [27] Anti-CD20 Antibody Therapy for B-Cell Lymphomas
    Taylor, Ronald P.
    Lindorfer, Margaret A.
    Zent, Clive S.
    NEW ENGLAND JOURNAL OF MEDICINE, 2012, 367 (09) : 876 - 877
  • [28] B cell activation influences antigen presentation, proinflammatory T cell polarization and response to anti-CD20 B cell depletion in CNS autoimmunity
    Martin, Weber
    Thomas, Prod'homme
    Carlos, Patarroyo Juan
    Nicolas, Molnarfi
    Tara, Karnezis
    Klaus, Lehmann-Horn
    Dimitry, Danilenko
    Jeffrey, Eastham-Anderson
    Anthony, Slavin
    Christopher, Linington
    Claude, Bernard
    Flavius, Martin
    Scott, Zamvil
    JOURNAL OF NEUROIMMUNOLOGY, 2010, 228 (1-2) : 136 - 136
  • [29] Comparison Of Two Dosing Schedules For Subcutaneous Injections Of Low-Dose Anti-CD20 Veltuzumab In Relapsed Immune Thrombocytopenia: Final Results Of a Phase I Study
    Liebman, Howard
    Bussel, James B.
    Saleh, Mansoor N.
    Horne, Heather
    Wegener, William A.
    Goldenberg, David M.
    BLOOD, 2013, 122 (21)
  • [30] Subcutaneous Injections of Low Doses of Humanized Anti-CD20 Veltuzumab for Treatment of Indolent B-Cell Malignancies
    Negrea, O. George
    Allen, Steven L.
    Rai, Kanti R.
    Elstrom, Rebecca
    Abassi, Rashid
    Farber, Charles M.
    Teoh, Nick
    Horne, Heather
    Wegener, William A.
    Goldenberg, David M.
    BLOOD, 2009, 114 (22) : 1446 - 1446
12345